Norway· NO-ID_6E155ECA-B8F8-4DFD-860D-A44B72F30B5E
Andembry
A garadacimab product containing garadacimab, registered in Norway by CSL Behring GmbH. The same ATC class is registered in 11 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Garadacimab is registered in 11 of 19 countries.
Countries holding a registration under ATC B06AC07 (garadacimab), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 7 of them publish a price we can compare per daily dose
Garadacimab · ATC B06AC07
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FEST (Norway)- Active substance
- Garadacimab
- Manufacturer
- CSL Behring GmbH
- Country
- Norway (NO)
- ATC code
- B06AC07
- ATC class
- Garadacimab
- Defined daily dose
- 6.7 mg, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- gtin4047725130946
- no_merkevare_idID_6E155ECA-B8F8-4DFD-860D-A44B72F30B5E
- no_varenummer1594501.2NOK 335005.5
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Garadacimab in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaANDEMBRYCSL Behring GmbH, Marburg
- BelgiumAndembry 200 mgCSL Behring
- IcelandAndembryCSL Behring GmbH*
- PolandAndembryCSL Behring GmbH
- SwedenANDEMBRY 200 mg Injektionsvätska, lösning i förfylld injektionspennaCSL Behring GmbH
- SpainANDEMBRY 200 MG SOLUCION INYECTABLE EN PLUMA PRECARGADACsl Behring Gmbh
- NetherlandsANDEMBRY 200 mg oplossing voor injectie in voorgevulde penCSL Behring GmbH
- FinlandANDEMBRYCSL Behring GmbH
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Andembry
- Liechtenstein · Andembry
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8a595e31-e403-4291-8a19-03b843bf5e69 GET /v1/drugs/8a595e31-e403-4291-8a19-03b843bf5e69?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Injeksjonsvæske, oppløsning i ferdigfylt penn",
"source": "fest",
"status": "A",
"atc_name": "Garadacimab",
"merkevare_id": "ID_6E155ECA-B8F8-4DFD-860D-A44B72F30B5E",
"name_form_strength": "Andembry inj, oppl 200 mg/penn",
"prescription_group": "C"
}See everything about garadacimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.